	US 12,472,180 B2
	Combinations for treatment of NAFLD/NASH and related diseases
Neeta Balkrishan Amin, Cambridge, MA (US); Arthur James Bergman, Salem, CT (US); Roberto Arnaldo Calle, Marlborough, MA (US); William Paul Esler, Clinton, CT (US); Albert Myung Kim, Newton, MA (US); Jeffrey Allen Pfefferkorn, Acton, MA (US); and Patrick Robert Verhoest, Newton, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Appl. No. 17/904,537
Filed by Pfizer Inc., New York, NY (US)
PCT Filed Feb. 22, 2021, PCT No. PCT/IB2021/051479 § 371(c)(1), (2) Date Aug. 18, 2022, PCT Pub. No. WO2021/171164, PCT Pub. Date Sep. 2, 2021.
Claims priority of provisional application 62/980,664, filed on Feb. 24, 2020.
Prior Publication US 2023/0218616 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 31/438 (2006.01); A61P 1/16 (2006.01); A61P 3/00 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 31/438 (2013.01); A61P 1/16 (2018.01); A61P 3/00 (2018.01); C07B 2200/13 (2013.01)]

17 Claims

1. A method for treating a disease or condition selected from fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, the method comprising the steps of:

administering to a human in need thereof a therapeutically effective amount of a composition comprising from about 5 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 60 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.